What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study
Menée à partir de l'analyse de l'ADN extrait d'échantillons sanguins prélevés sur 2 929 et 1 948 patients atteints d'un cancer colorectal, cette étude analyse l'association entre des variants constitutionnels altérant la fonction de trois récepteurs de reconnaissance de motifs moléculaires (FRP1, TLR3 ou TLR4) et le bénéfice, en termes de survie, de l'oxaliplatine
Over the past decade, the growing knowledge of colorectal cancer (CRC) molecular characteristics and complex genomic makeup has prompted a widespread effort to identify predictive biomarkers for available therapeutic agents while supporting the rationale for the development of new targeted therapies and treatment combinations. Pharmacogenomics represents an irreplaceable tool to tailor patient treatment based on germline and somatic genetic variations that can predict drug response and risk of toxicities. Several pharmacogenomic biomarkers, including single nucleotide polymorphisms (SNPs) in genes involved in key oncogenic mechanisms, drug metabolism, and tumor-microenvironment interaction, have shown promising results in different settings so far; nevertheless, their clinical validation is often lacking.
Journal of the National Cancer Institute , commentaire en libre accès, 2018